On Nov 19, major Wall Street analysts update their ratings for $Regenxbio (RGNX.US)$, with price targets ranging from $18 to $50.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and maintains the target price at $22.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $28 to $25.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $50.
Raymond James analyst Danielle Brill maintains with a buy rating, and maintains the target price at $18.
Leerink Partners analyst Mani Foroohar maintains with a buy rating, and adjusts the target price from $34 to $38.
Furthermore, according to the comprehensive report, the opinions of $Regenxbio (RGNX.US)$'s main analysts recently are as follows:
The attractiveness of gene therapy for VEGF-mediated diseases is acknowledged due to the unmet need. However, the potential limitations of subretinal delivery on commercial uptake are noted, and it's mentioned that the data on suprachoroidal delivery is still preliminary. The upcoming first functional results for RGX-202 in Duchenne muscular dystrophy will be discussed in a company webcast.
Here are the latest investment ratings and price targets for $Regenxbio (RGNX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
